Skip to main content
Midas Edge

NRX Pharmaceuticals, Inc.

For the period ended Jun 30, 2026. Filed Aug 14, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 14, 2026

NRXP$2.36-0.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Legal Proceedings

Item 1. Legal Proceedings

See Note 10, Commitments and Contingencies, of the notes to the Company’s unaudited condensed consolidated financial statements as of and for the six months ended June 30, 2026 included elsewhere in this report for further discussion of certain legal proceedings in which we are involved.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.